BofA analyst Alec Stranahan downgraded Y-mAbs Therapeutics (YMAB) to Underperform from Neutral with a price target of $3, down from $12.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-Mabs Therapeutics: Promising Pipeline and Positive Financial Outlook Justify Buy Rating
- Y-mAbs Therapeutics price target lowered to $12 from $22 at H.C. Wainwright
- Positive Outlook on Y-Mabs Therapeutics Despite Adjusted Price Target, Driven by Promising Radiopharmaceutical Platform
- Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA
- Y-mAbs Therapeutics price target lowered to $18 from $21 at Truist